Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral thera...
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Takeda
- Registration Number
- NCT04392648
INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2020-08-19
- Lead Sponsor
- Medical College of Wisconsin
- Registration Number
- NCT04355039
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
- Conditions
- Interventions
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 40
- Registration Number
- NCT04302324
- Locations
- 🇺🇸
Weill Cornell Medicine - Multiple Myeloma Center, New York, New York, United States
Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Poitiers University Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT04287855
- Locations
- 🇫🇷
CHU Poitiers, Poitiers, France
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
- Conditions
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 21
- Registration Number
- NCT04270175
- Locations
- 🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States
🇺🇸Weill Cornell Medicine - Multiple Myeloma Center, New York, New York, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
- Conditions
- Interventions
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 54
- Registration Number
- NCT04191616
- Locations
- 🇫🇷
Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez, Lille Cedex, France
🇬🇷University Hospital of Ioannina, Ioannina, Greece
🇮🇹Azienda Unita Sanitaria Locale LE Presidio Ospedaliero Vito Fazzi Polo Oncologico Giovanni Paolo II, Lecce, Italy
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-12-02
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 419
- Registration Number
- NCT04181827
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Cancer Center-Scottsdale, Phoenix, Arizona, United States
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
- Conditions
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Andrew Yee, MD
- Target Recruit Count
- 43
- Registration Number
- NCT04176718
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 464
- Registration Number
- NCT04126200
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Fondazione EMN Italy Onlus
- Target Recruit Count
- 45
- Registration Number
- NCT04124497
- Locations
- 🇮🇹
Ospedali Riuniti, Bergamo, Italy
🇮🇹Istituto Clinico Humanitas, Rozzano, Italy
🇮🇹Policlinico Universitario di Udine, Udine, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.